Arabic Arabic English English French French German German
dark

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

Mustang Bio, Inc. (“Mustang”) today announced that the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

OAG report into vaccine programme ‘useful and timely’ says Ministry

Next Post

Kelyniam Global Releases Q1 Financial Results – Profitability Despite the 2nd Wave Pandemic

Related Posts
Total
0
Share